Dr Hugh Marston

Currently SVP & Global Head of CNS Diseases Research at Boehringer Ingelheim Hugh trained as a psychopharmalogist (TW Robbins, Cambridge) exploring cholinergic circuitry & cognition. After a fellowship at NIDA (USA), substrates of cocaine addiction, he moved to Uni. of Edinburgh & the Fujisawa Institute investigating somatostatin and adenosine’s role in cognition, neuroprotection by FK506 in stroke & VPAC2R in circadian behaviour. Next Organon to head neurobiology and help take Asenapine and Sugammadex to market, as well as GlyT1, GR & AMPA into man. Organon became Schering-Plough became Merck & Newhouse closed in 2011. At TPP, a micropharma, as Head of Pharmacology, the team developed novel IDO inhibitors from scratch acquired clinic ready by Merck. As Head of Translational Neuroscience at Lilly his team worked on D1 PAMs, neurodegenerative and pain targets including amyloid, tau & CGRP. At BI he leads a new Precision Psychiatry approach (GlyT1 Ph3, TrpC4/5 Ph2) transdiagnostically, targeting specific CNS circuits. The focus, as through his whole career, being the proper translation from the patient’s biology as illustrated by the IMI PRISM project that he has led from inception.